Palonosetron versus older 5-HT3 receptor antagonists for nausea prevention in patients receiving chemotherapy: a multistudy analysis

Gr, Morrow; Schwartzberg, Lee S.; Barbour, SY; Ballinari, Gianluca; Cox, D.

doi:10.12788/jcso.0058

Cited by 5 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Palonosetron is a newer congener of ondansetron with a longer half-life of around 40 hours and has not been associated with significant QT interval prolongation. 6 Dexamethasone is a steroidal anti-inflammatory agent that has a central antiemetic action through the activation of glucocorticoid receptor in nuclei tractus solitarius in medulla. It decreases levels of 5-HT3 in neural tissue and in the gut and is commonly used as an antiemetic agent in cancer chemotherapy and PONV.…”

Section: Materials a N D Methodsmentioning

confidence: 99%

“…5 It has not been associated with significant QT interval prolongation, an effect observed with other 5-HT3 receptor antagonists. 6 Dexamethasone has a central antiemetic action through the activation of glucocorticoid receptor in nuclei tractus solitarius in medulla. Dexamethasone has low cost and prolonged biological half-life of 36-48 hours.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Frequency of Postoperative Nausea and Vomiting after General Anesthesia in a Tertiary Care Hospital: A Comparison of Palonosetron and Dexamethasone

Kumari¹,

Kaur²,

Nagi³

2021

AMEI's Current Trends in Diagnosis &Amp; Treatment

View full text Add to dashboard Cite

Introduction: Postoperative nausea and vomiting (PONV) is an unpleasant sensation often described as worse than postoperative pain. Various drugs, including scopolamine, gabapentin, dexamethasone, metoclopramide, promethazine, haloperidol, and serotonin receptor antagonists, have been used for prophylaxis of PONV, but none has been 100% efficacious. We hereby try to compare the effects of palonosetron and dexamethasone on the frequency of PONV. Aims and objectives: The aim of our study was to compare the frequency of PONV with palonosetron and dexamethasone in patients undergoing elective laparoscopic cholecystectomy surgery under general anesthesia. Material and methods: In this prospective, randomized, double-blind study, 50 patients scheduled for laparoscopic cholecystectomy were randomized into two groups receiving 8 mg dexamethasone or 0.075 mg palonosetron. The frequency of PONV in the two groups was compared. Results: Statistical analysis was done using SPSS version 20 (SPSS Inc., Chicago, Illinois, USA).The patients in the two groups were comparable in terms of mean age, body mass index, and gender distribution. At 4, 8, and 12 hours, the incidence of PONV was significantly less in patients receiving palonosetron than those receiving dexamethasone (p = 0.007, 0.001, 0.001, respectively). Conclusion:We can conclude from the present study that 0.075 mg palonosetron is more effective than 8 mg dexamethasone to reduce the incidence of PONV after laparoscopic cholecystectomy.

show abstract

Section: Materials a N D Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Frequency of Postoperative Nausea and Vomiting after General Anesthesia in a Tertiary Care Hospital: A Comparison of Palonosetron and Dexamethasone

Kumari¹,

Kaur²,

Nagi³

2021

AMEI's Current Trends in Diagnosis &Amp; Treatment

View full text Add to dashboard Cite

show abstract

“…It appears that the serotonin 5-HT 3 receptor may not be of major importance in mediating nausea. In a retrospective multistudy analysis, Morrow et al [51] suggested that palonosetron may be more effective than the first-generation 5-HT 3 receptor antagonists in the prevention of nausea, but there was no statistically significant difference among the first-generation 5-HT 3 receptor antagonists and palonosetron in the prevention of nausea in the multistudy analysis. Saito et al [31] reported an improvement in 'no nausea' in the delayed and overall periods after HEC in patients who received palonosetron plus dexamethasone compared to patients receiving granisetron plus dexamethasone, but the magnitude of the control was low ( Table 3).…”

Section: Prevention and Treatment Of Nausea With Palonosetronmentioning

confidence: 98%

Palonosetron for the treatment of chemotherapy-induced nausea and vomiting

Navari

2014

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

The clinical data in the literature have established palonosetron as the 5-HT3 receptor antagonist of choice in terms of efficacy and safety for the prevention of CINV for patients receiving moderately or highly emetogenic chemotherapy. Three international guidelines have listed palonosetron as the preferred 5-HT3 receptor antagonist. Due to its higher efficacy, the use of palonosetron may be more cost effective compared to the generic first-generation 5-HT3 receptor antagonists. Clinical organizations' pharmacy and formulary committees should consider efficacy when making recommendations for agents for the prevention of CINV.

show abstract

The use of aprepitant and palonosetron in preventing chemotherapy-related nausea and vomiting inlung cancer patients

Zheng

Liu

et al. 2017

Oncology and Translational Medicine

View full text Add to dashboard Cite

ObjectiveThe aim of this study was to explore the clinical efficacy and toxicity of a combination aprepitant and palonosetron hydrochloride therapy in preventing chemotherapy-induced nausea and vomiting associated with a cisplatinum-based regimen in patients with lung cancer.MethodsSixty-eight patients with lung cancer were randomly assigned to receive either aprepitant plus palonosetron hydrochloride (group A, n = 38) or tropisetron (group B, n = 30). Acute (0-24 h) and delayed (2-5 d) emetic episodes, nausea, vomiting, constipation, and dizziness were compared between the two groups in the five days following cisplatinum-based chemotherapy.ResultsGroup A had a higher complete control rate for both acute and delayed emetic episodes than Group B (36.8% vs. 13.3% and 31.6% vs. 13.3%, respectively; P < 0.05 for both). There was no significant difference in the constipation rate between the two groups.ConclusionAprepitant combined with palonosetron hydrochloride is active and well tolerated in both acute and delayed emetic episodes in patients with lung cancer treated by a cisplatinum-based regimen.

show abstract

Palonosetron versus older 5-HT3 receptor antagonists for nausea prevention in patients receiving chemotherapy: a multistudy analysis

Abstract: Background-No clinical standard currently exists for the optimal management of nausea induced by emetogenic chemotherapy, particularly delayed nausea.

Cited by 5 publications

References 30 publications

Frequency of Postoperative Nausea and Vomiting after General Anesthesia in a Tertiary Care Hospital: A Comparison of Palonosetron and Dexamethasone

Frequency of Postoperative Nausea and Vomiting after General Anesthesia in a Tertiary Care Hospital: A Comparison of Palonosetron and Dexamethasone

Palonosetron for the treatment of chemotherapy-induced nausea and vomiting

The use of aprepitant and palonosetron in preventing chemotherapy-related nausea and vomiting inlung cancer patients

Contact Info

Product

Resources

About